committed to building on her work to help lower prescription drug costs
Lower prescription drug costs for Kansans.
Occurrences
I will keep fighting to lower the cost of prescription drugs and to keep politicians out of our most personal health care decisions.
Evidence
Davids says she is dedicated to lowering the cost of health care and prescription drugs, and notes she voted to allow Medicare to negotiate for lower drug prices and to cap insulin at $35 a month for seniors.
The House roll call for H.R. 5376 shows Sharice Davids (KS) voted yea on passage of the Build Back Better Act.
The enrolled bill for H.R. 5376 is the Inflation Reduction Act enactment, the law that created Medicare prescription drug price negotiation and other drug-cost reductions.
Davids introduced H.R. 5894, which would require drug list prices to be included in advertisements and direct HHS to issue drug-price transparency guidance; the bill was referred to committee.
Assessments
The promise was broad but substantively fulfilled in federal office context because Davids voted for H.R. 5376, the Inflation Reduction Act, which was enacted in 2022 and created major prescription drug cost reductions including Medicare drug price negotiation and insulin cost caps for seniors. Her earlier standalone transparency bill did not advance, but the enacted IRA provisions directly address lowering prescription drug costs and passed while she remained in office, so the outcome warrants full delivery rather than only effort or partial credit.
Davids supported and voted for major federal prescription drug cost measures that became law through the Inflation Reduction Act, including Medicare drug price negotiation and a $35 insulin cap for seniors. Those policies plausibly lowered prescription drug costs for some Kansans, especially Medicare beneficiaries, during the same congressional term. However, the promise was broad and not fully delivered for all Kansans or across prescription drug costs generally, and one separate Davids drug-price transparency bill did not advance beyond committee referral.